Mohammad Razaq, MD
Targeted therapies have transformed the outlook of EGFR
, and ROS1
-driven advanced non–small cell lung cancers (NSCLC), said Mohammad Razaq, MD. Moreover, the availability of broad molecular tissue- and blood-based panels could enable a similar fruition of targeted agents for patients with less common alterations.
... to read the full story